An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE).

Trial Profile

An Exploratory Study to Evaluate Changes in Disease Activity and Biomarkers During Treatment With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE).

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2014

At a glance

  • Drugs Paquinimod (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 26 May 2011 Results have been presented at EULAR-2011 according to an Active Biotech AB media release.
    • 19 Oct 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 16 Sep 2010 An update on this trial will be presented at the UBS Global Life Sciences Conference, September 2010, according to an Active Biotech media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top